RxDoctor Payments Data

Kenneth Ejiogu

Family · Los Angeles, CANPI 1639647019

Payments from drug & device makers

$678in general payments, 2019–2025

Across 43 payments — averaging $15.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$570
  • AbbVie$38
  • Collegium Pharmaceutical, Inc.$24
  • Abbott$23
  • Virtus Pharmaceuticals LLC$22

What the payments were for

  • Food & beverage$678100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC38$570
AbbVie2$38
Collegium Pharmaceutical, Inc.1$24
Abbott1$23
Virtus Pharmaceuticals LLC1$22

How this compares

$678 in reported general payments places this provider in the 65th percentile of 10,634 family providers in California.

See all family providers in California

Medicare billing

Part B allowed, 2024
$248,942
Medicare patients
415
Services billed
4,222

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RelistorMethylnaltrexone Bromide79$186,885
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen1,427$33,825
LinzessLinaclotide61$31,989
Diclofenac Sodium187$25,702
QuliptaAtogepant20$20,962
Lidocaine126$9,970
Buprenorphine28$7,999
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen200$6,170
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl29$5,326
Gabapentin561$5,050
ZtlidoLidocaine12$4,579
MovantikNaloxegol Oxalate12$4,551
Butalb-Acetaminoph-Caff-CodeinButalbit/Acetamin/Caff/Codeine13$2,696
Baclofen233$1,950
Cyclobenzaprine Hcl273$1,746

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCRelistor$570$186,88579 claims
AbbVieLinzess, Qulipta$38$52,95281 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 10,634 family providers in California.

Other family in Los Angeles

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →